GSK Shingrix Shingles Vaccine Seen Displacing Zostavax After US FDA Approval

 
• By Sten Stovall

US FDA OK for its two-shot shingles regime gives GSK a likely blockbuster with a clear best-in-class profile.

Shingles_1200
GSK's Shingrix is a big improvement on the existing shingles vaccine, Zostavax • Source: Shutterstock

GlaxoSmithKline PLC will have a promising new money-spinner to crow about on Oct 25 when it reports third-quarter results after the FDA approved its highly efficient shingles vaccine Shingrix, which analysts expect to become a blockbuster.

The vaccine's approval covers people 50 years or older, as a prevention tool against the painful, blistering rash. Shingles is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip